Jane Street Group LLC Has $260,000 Stock Position in MaxCyte, Inc. (NASDAQ:MXCT)

Jane Street Group LLC lowered its position in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 43.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,868 shares of the company’s stock after selling 50,716 shares during the quarter. Jane Street Group LLC owned approximately 0.06% of MaxCyte worth $260,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Marshall Wace LLP acquired a new stake in MaxCyte in the 2nd quarter valued at about $1,959,000. ArrowMark Colorado Holdings LLC boosted its stake in MaxCyte by 13.8% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock worth $5,426,000 after acquiring an additional 169,250 shares during the last quarter. Mudita Advisors LLP boosted its stake in MaxCyte by 5.6% during the 3rd quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock worth $12,267,000 after acquiring an additional 167,101 shares during the last quarter. Royce & Associates LP boosted its stake in MaxCyte by 59.8% during the 3rd quarter. Royce & Associates LP now owns 323,924 shares of the company’s stock worth $1,260,000 after acquiring an additional 121,272 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in MaxCyte by 13.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock worth $3,961,000 after acquiring an additional 121,090 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Trading Down 3.7 %

Shares of MXCT opened at $4.40 on Friday. MaxCyte, Inc. has a 12 month low of $3.16 and a 12 month high of $5.55. The firm has a fifty day simple moving average of $3.90 and a 200 day simple moving average of $4.02. The stock has a market capitalization of $465.13 million, a price-to-earnings ratio of -12.94 and a beta of 1.29.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The firm had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. During the same period last year, the company earned ($0.11) earnings per share. As a group, research analysts predict that MaxCyte, Inc. will post -0.42 earnings per share for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.